Responses to O-FC by pretreatment characteristics and number of treatment courses received
Characteristic . | n* . | CR rate, % . | OR rate, % . |
---|---|---|---|
All patients | 61 | 41 | 75 |
Sex | |||
Male | 43 | 35 | 70 |
Female | 18 | 56 | 89 |
Age, y | |||
< 65 | 50 | 44 | 76 |
≥ 65 | 11 | 27 | 73 |
ECOG performance status | |||
0 | 34 | 47 | 82 |
1-2 | 27 | 33 | 67 |
Palpable lymph nodes | |||
≤ 5 cm | 51 | 39 | 78 |
> 5 cm | 10 | 50 | 60 |
Rai stage | |||
0-II | 33 | 36 | 73 |
III-IV | 28 | 46 | 79 |
Binet stage | |||
A | 8 | 38 | 75 |
B | 33 | 42 | 79 |
C | 20 | 40 | 70 |
β-2M† | |||
< 4 mg/L | 32 | 53 | 84 |
≥ 4 mg/L | 28 | 29 | 68 |
Lactate dehydrogenase† | |||
< 228 IU/L | 30 | 40 | 77 |
≥ 228 IU/L | 31 | 42 | 74 |
Thymidine kinase† | |||
< 29 IU/L | 29 | 45 | 76 |
≥ 29 IU/L | 30 | 40 | 80 |
ALC† | |||
< 90 × 109/L | 31 | 45 | 81 |
≥ 90 × 109/L | 30 | 37 | 70 |
CD38 expression (%) | |||
< 30 | 48 | 44 | 77 |
≥ 30 | 12 | 33 | 67 |
IGHV mutation status | |||
Mutated | 28 | 46 | 75 |
Unmutated‡ | 25 | 36 | 84 |
FISH genomic abnormalitym§ | |||
17p del | 8 | 13 | 63 |
11q del | 10 | 40 | 70 |
Trisomy 12q | 8 | 63 | 63 |
No abnormality | 7 | 71 | 100 |
13q del (sole) | 25 | 32 | 80 |
O-FC courses received, no. | |||
6 | 39 | 56‖ | 92‖ |
4-5 | 9 | 33 | 78 |
1-3 | 13 | 0 | 23 |
Characteristic . | n* . | CR rate, % . | OR rate, % . |
---|---|---|---|
All patients | 61 | 41 | 75 |
Sex | |||
Male | 43 | 35 | 70 |
Female | 18 | 56 | 89 |
Age, y | |||
< 65 | 50 | 44 | 76 |
≥ 65 | 11 | 27 | 73 |
ECOG performance status | |||
0 | 34 | 47 | 82 |
1-2 | 27 | 33 | 67 |
Palpable lymph nodes | |||
≤ 5 cm | 51 | 39 | 78 |
> 5 cm | 10 | 50 | 60 |
Rai stage | |||
0-II | 33 | 36 | 73 |
III-IV | 28 | 46 | 79 |
Binet stage | |||
A | 8 | 38 | 75 |
B | 33 | 42 | 79 |
C | 20 | 40 | 70 |
β-2M† | |||
< 4 mg/L | 32 | 53 | 84 |
≥ 4 mg/L | 28 | 29 | 68 |
Lactate dehydrogenase† | |||
< 228 IU/L | 30 | 40 | 77 |
≥ 228 IU/L | 31 | 42 | 74 |
Thymidine kinase† | |||
< 29 IU/L | 29 | 45 | 76 |
≥ 29 IU/L | 30 | 40 | 80 |
ALC† | |||
< 90 × 109/L | 31 | 45 | 81 |
≥ 90 × 109/L | 30 | 37 | 70 |
CD38 expression (%) | |||
< 30 | 48 | 44 | 77 |
≥ 30 | 12 | 33 | 67 |
IGHV mutation status | |||
Mutated | 28 | 46 | 75 |
Unmutated‡ | 25 | 36 | 84 |
FISH genomic abnormalitym§ | |||
17p del | 8 | 13 | 63 |
11q del | 10 | 40 | 70 |
Trisomy 12q | 8 | 63 | 63 |
No abnormality | 7 | 71 | 100 |
13q del (sole) | 25 | 32 | 80 |
O-FC courses received, no. | |||
6 | 39 | 56‖ | 92‖ |
4-5 | 9 | 33 | 78 |
1-3 | 13 | 0 | 23 |
ALC indicates absolute lymphocyte count; and FISH, fluorescence in situ hybridization.
Patient numbers do not add up to N = 61 for some of the categories due to missing assessments.
Cutoff values were based on median levels at baseline.
Defined as ≥ 98% homology to closest germline sequence.
Based on Dohner hierarchy.24
P < .05, Fisher's exact test.